Design Therapeutics (DSGN) Operating Leases (2021 - 2026)

Design Therapeutics has disclosed Operating Leases across 6 years of filings, most recently posting $2.2 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $2.2 million, up 66.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.2 million (up 66.52% YoY), and the FY2025 annual result was $645000.0, down 57.95% from the prior year.
• Operating Leases came in at $2.2 million for Q1 2026 at Design Therapeutics, up from $645000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $3.4 million in Q2 2022 to a low of $645000.0 in Q4 2025.
• The 5-year median for Operating Leases is $2.2 million (2026), against an average of $2.2 million.
• Across the five-year window, Operating Leases slumped 57.95% in 2025 and surged 66.52% in 2026, its largest moves.
• Design Therapeutics' Operating Leases stood at $3.1 million in 2022, then fell by 23.5% to $2.3 million in 2023, then slumped by 34.28% to $1.5 million in 2024, then plunged by 57.95% to $645000.0 in 2025, then soared by 240.78% to $2.2 million in 2026.
• The last three Operating Leases figures came in at $2.2 million (Q1 2026), $645000.0 (Q4 2025), and $877000.0 (Q3 2025), per Business Quant data.